Pharmacological perturbation of CXCL1 signaling alleviates neuropathogenesis in a model of HEVA71 infection

纳米颗粒;亨廷顿氏病
浏览次数:4 分享:

Saravanan Gunaseelan, Mohammed Zacky Ariffin, Sanjay Khanna, Mong How Ooi, David Perera, Justin Jang Hann Chu, John Jia En Chua

  • Nat Commun
  • 17.694
  • 13(1):890.
  • Rat
  • Luminex
  • 神经系统
  • G-CSF,GM-CSF,GRO/KC,IFN-γ,IL-1α,IL-1β,IL-2,IL-4,IL-5,IL-6,IL-7,IL-10,IL-12 (p70),IL-13,IL-17A,IL-18,M-CSF,MCP-1,MIP-1α,MIP-3α,RANTES,TNF-α,VEGF

相关货号

LXLBR23-1

Abstract

Hand, foot and mouth disease (HFMD) caused by Human Enterovirus A71 (HEVA71) infection is typically a benign infection. However, in minority of cases, children can develop severe neuropathology that culminate in fatality. Approximately 36.9% of HEVA71-related hospitalizations develop neurological complications, of which 10.5% are fatal. Yet, the mechanism by which HEVA71 induces these neurological deficits remain unclear. Here, we show that HEVA71-infected astrocytes release CXCL1 which supports viral replication in neurons by activating the CXCR2 receptor-associated ERK1/2 signaling pathway. Elevated CXCL1 levels correlates with disease severity in a HEVA71-infected mice model. In humans infected with HEVA71, high CXCL1 levels are only present in patients presenting neurological complications. CXCL1 release is specifically triggered by VP4 synthesis in HEVA71-infected astrocytes, which then acts via its receptor CXCR2 to enhance viral replication in neurons. Perturbing CXCL1 signaling or VP4 myristylation strongly attenuates viral replication. Treatment with AZD5069, a CXCL1-specific competitor, improves survival and lessens disease severity in infected animals. Collectively, these results highlight the CXCL1-CXCR2 signaling pathway as a potential target against HFMD neuropathogenesis.
金课堂之文献解析 文献原文请点击

技术文章 更多

    研究领域 更多

      热点文献